Western Suburbs Neurosciences Clinical Trials

Neurosciences Clinical Trials

Western Suburbs Neurosciences Clinical Trials

Through ongoing medical research, patients with neurological conditions are finding new ways to live longer and better. If you or someone you love is living with Parkinson’s disease, epilepsy, Tourette’s syndrome or the side effects of stroke, Northwestern Medicine offers a range of promising neuroscience clinical trials right in the community that may help improve quality of life.

If you find a clinical trial that interests you, talk with your physician or call or email the contact listed. For more information, please call 630.933.6107. TTY for the hearing impaired 630.933.4833.

Current Neuroscience Clinical Trials

Through the physicians on the medical staff at Northwestern Medicine Central DuPage Hospital and Northwestern Medicine Delnor Hospital, you have convenient access to a wide variety of neurosciences clinical trials. For ease of searching, the current research studies are sorted into the following categories:

  • Aneurysms
  • Brain Tumors
  • Humanitarian Use Devices
  • Multiple Sclerosis (MS)
  • Parkinson’s Disease
  • Stroke
  • Other Neurosciences

View Trials

Study: Prospective, Multi-Center, Single-Arm Study of the Reverse Medical Barrel™ Vascular Reconstruction Device (VRD) for Adjunctive Treatment to Embolic Coils for Wide-Neck, Intracranial, Bifurcating/Branching Aneurysms of Middle Cerebral and Basilar Arteries.
Clinical Trial #: NCT02179190, Medtronic
Principal Investigator: Harish N. Shownkeen, MD
Contact: Komal Sharma, CRC, Komal.sharma@nm.org or Kathy Hansen, RN, CRC, Kathy.hansen@nm.org, 630.933.6107

Learn more at Clinicaltrials.gov2


Study: Pivotal Study of the MicroVention Flow Re-Direction (FRED) Endoluminal Device Stent System in the Treatment of Intracranial Aneurysms
Clinical Trial #: NCT01801007
Principal Investigator: Harish N. Shownkeen, MD
Contact: Komal Sharma, CRC, Komal.sharma@nm.org or Kathy Hansen, RN, CRC, Kathy.hansen@nm.org, 630.933.6107

Learn more at Clinicaltrials.gov2


Study: Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations
Clinical Trial #: A071401
Principal Investigator: Sean Grimm, MD

Learn more at Clinicaltrials.gov2


Study: A Randomized Phase III Trial of Memantine And Whole-Brain Radiotherapy With Or Without Hippocampal Avoidance In Patients With Brain Metastases
Clinical Trial #: CC001
Principal Investigator: Vinai Gondi, MD1

Learn more at Clinicaltrials.gov2


Study: Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy versus Conventional Photon Irradiation with Concomitant and Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma.
Clinical Trial #: NRG-BN001
Principal Investigator: Vinai Gondi, MD1

Learn more at Clinicaltrials.gov2


Study: A study to determine whether adding radiation to bevacizumab is more effective than using bevacizumab alone to treat recurrent glioblastomas.
Clinical Trial #: RTOG 1205
Principal Investigator: Vinai Gondi, MD1
Contact: Claudine Gamster, BS, CCRP, 630.315.1918, TTY for hearing impaired 630.933.4833, claudine.gamster@nm.org

Learn more at Clinicaltrials.gov2


Study: A Phase II Study of the Efficacy of Hypofractionated Radiation Therapy with Bevacizumab and Temozolomide Followed by Maintenance Temozolomide and Bevacizumab for Recurrent High-Grade Gliomas.
Clinical Trial #: NU 11C02
Principal Investigator: Vinai Gondi, MD1
Contact: Claudine Gamster, BS, CCRP, 630.315.1918, TTY for hearing impaired 630.933.4833, claudine.gamster@nm.org

Learn more at Cancer.gov2


Study: A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) (NSC#725085, Alliance IND# 15380) Vaccine Given with Bevacizumab Versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM).
Clinical Trial #: Protocol A071101
Principal Investigator: Sean Grimm, MD
Contact: Claudine Gamster, BS, CCRP, 630.315.1918, TTY for hearing impaired 630.933.4833, claudine.gamster@nm.org

Learn more at Clinicaltrials.gov2


Study: A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme.
Clinical Trial #: Protocol 020221
Principal Investigator: Sean Grimm, MD
Contact: Claudine Gamster, BS, CCRP, 630.315.1918, TTY for hearing impaired 630.933.4833, claudine.gamster@nm.org

Learn more at Clinicaltrials.gov2


Study: A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) to Reduce Cancer-Related Fatigue in Patients with High Grade Glioma.
Clinical Trial #: Protocol A221101
Principal Investigator: Sean Grimm, MD
Contact: Claudine Gamster, BS, CCRP, 630.315.1918, TTY for hearing impaired 630.933.4833, claudine.gamster@nm.org

Learn more at Clinicaltrials.gov2


Pediatric Brain Tumor

Study: Quality of Life Symptoms Experienced by Children with Brain Tumors in Comparison to the National Reference.
Clinical Trial #: Protocol STU00085313
Principal Investigator: John Chang, MD1
Contact: Claudine Gamster, BS, CCRP, 630.315.1918, TTY for hearing impaired 630.933.4833, claudine.gamster@nm.org


A Humanitarian Use Device (HUD) is intended for use in patients with conditions that affect less than 4,000 people in the United States and there is no comparable device marketed to treat/diagnose those conditions or diseases. Since the number of patients is so small, the Food and Drug Administration (FDA) has approved the use of HUDs for the clinical treatment of patients without the same amount of testing that other products get. The ability of this device to treat your condition has not been proven, but the FDA believes that these devices are likely to be safe and will probably benefit patients.

Aneurysm

Study: LVIS and LVIS JR: Microvention Low-profile Visualized /ntraluminal Support (LVIS®) or LVIS Jr. Humanitarian Use Device ("LVIS HUD")
Treatment: The LVlS HUD is a metal mesh called a "stent," that is indicated for use with bare platinum embolic coils for the treatment of unruptured, wide-neck (neck >4 mm or dome to neck ratio <2 mm), intracranial, saccular aneurysms arising from a parent vessel with a diameter >2.5 mm and <4.5
Principal Investigator: Harish N. Shownkeen, MD

Learn more at FDA.gov2


Aneurysm

Study: Neuroform: Microdelivery Stent System
Treatment: The Neuroform stent can be placed in a brain artery across the opening of an aneurysm. After the stent is in place, the aneurysm sac can be filled with small metal coils. The coils prevent blood from flowing into the aneurysm and could greatly reduce the risk of aneurysm rupture. The Neuroform stent is a small metallic mesh tube that is designed to keep the coils in the aneurysm sac.
Principal Investigator: Harish N. Shownkeen, MD

Learn more at FDA.gov2


Aneurysm

Study: CODMAN ENTERPRISE: TM Vascular Reconstruction Device and Delivery System
Treatment: The ENTERPRISE TM Vascular Reconstruction Device and Delivery System stent can be placed in a brain artery across the opening of an aneurysm. After the stent is in place, the aneurysm sac can be filled with small metal coils. The coils prevent blood from flowing into the aneurysm and could greatly reduce the risk of aneurysm rupture. The stent is a small metallic mesh tube that is designed to keep the coils in the aneurysm sac to aid in treating your wide-neck, intracranial, saccular or fusiform aneurysms.
Principal Investigator: Harish N. Shownkeen, MD

Learn more at FDA.gov2


Aneurysm

Study: Onyx: Onyx Liquid Embolic System
Treatment: Onyx Liquid Embolic System is a non-adhesive liquid material that is inserted into an aneurysm (saclike bulging on one side of an artery) to block blood flow into the aneurysm and to attempt to prevent it from rupturing (bursting).
Principal Investigator: Harish N. Shownkeen, MD

Learn more at FDA.gov2


Stroke

Study: NeuroFlo: Perfusion Augmentation for Cerebral Vasospasm
Treatment: The treatment of cerebral ischemia resulting from symptomatic vasospasm following aneurismal subarachnoid hemorrhage secured by either surgical or endovascular intervention for patients who have failed maximal medical management.
Principal Investigator: Harish N. Shownkeen, MD

Learn more at FDA.gov2

Study: ESTEEM: A Multicenter, Global, Observational Study to Collect Information on Safety and to Document the Drug Utilization of Tecfidera™ (Dimethyl Fumarate) When Used in Routine Medical Practice in the Treatment of Multiple Sclerosis.
Clinical Trial #: NCT02047097
Principal Investigator: Mircea Tudor Iacob, MD
Contact: Komal Sharma, CRC, Komal.sharma@nm.org or Kathy Hansen, RN, CRC, Kathy.hansen@nm.org, 630.933.6107

Learn more at Clinicaltrials.gov2


Intercranial Stenosis

Study: WEAVE: Wingspan Stent system Post Market Surveillance Study.
Clinical Trial #: NCT02034058
Principal Investigator: Harish N. Shownkeen, MD
Contact: Komal Sharma, CRC, Komal.sharma@nm.org or Kathy Hansen, RN, CRC, Kathy.hansen@nm.org, 630.933.6107

Learn more at Clinicaltrials.gov2


Study: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Examine the Efficacy, Safety and Tolerability of APL-130277 in Levodopa Responsive Patients with Parkinson’s Disease Complicated by Motor Fluctuations (“OFF” Episodes)
Clinical Trial #: NCT02469090
Principal Investigator: Martha T. McGraw, MD
Contact: Komal Sharma, CRC, Komal.sharma@nm.org or Kathy Hansen, RN, CRC, Kathy.hansen@nm.org, 630.933.6107

Learn more at Clinicaltrials.gov2


Study: Cynapsus 301: An Open Label, Phase 3 Study Examining the Long-Term Safety, Tolerability and Efficacy of APL-130277 in Levodopa Responsive Patients with Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes)
Clinical Trial #: NCT02542696
Principal Investigator: Martha T. McGraw, MD
Contact: Komal Sharma, CRC, Komal.sharma@nm.org or Kathy Hansen, RN, CRC, Kathy.hansen@nm.org, 630.933.6107

Learn more at Clinicaltrials.gov2


Study: SURE PD3 A randomized, double-blind, placebo-controlled trial of urate elevating Inosine treatment to slow clinical decline in early Parkinson's disease (PD) (Protocol No: INO-PD-P3-2014)
Clinical Trial #: NCT02642393
Principal Investigator: Michael Rezak, MD
Contact: Komal Sharma, CRC, Komal.sharma@nm.org or Kathy Hansen, RN, CRC, Kathy.hansen@nm.org, 630.933.6107

Learn more at Clinicaltrials.gov2


Study: RESTORE: A clinical study of patients with symptomatic neuRogenic orthostatic hypotEnsion to assess Sustained effecTs Of dRoxidopa therapy
Clinical Trial #: NCT02586623
To treat patients with the following: Parkinson's Disease (PD), Multiple System Atrophy (MSA) or Pure Autonomic Failure(PAF), or Non-Diabetic Autonomic Neuropathy (NDAN) or Dopamine Beta Hydroxylase (DBH) deficiency.
Principal Investigator: Martha T. McGraw, MD
Contact: Komal Sharma, CRC, Komal.sharma@nm.org or Kathy Hansen, RN, CRC, Kathy.hansen@nm.org, 630.933.6107

Learn more at Clinicaltrials.gov2


Acute Stroke

Study: A randomized, concurrent controlled trial to assess the safety and effectiveness of the Separator 3D as a component of the Penumbra System in the revascularization of large vessel occlusion in acute ischemic stroke
Clinical Trial #: NCT01584609
Principal Investigator: Harish N. Shownkeen, MD
Contact: Komal Sharma, CRC, Komal.sharma@nm.org or Kathy Hansen, RN, CRC, Kathy.hansen@nm.org, 630.933.6107

Learn more at Clinicaltrials.gov2


Stroke

Study: PROSPER (Patient-centered Research into Outcomes Stroke patients Prefer and Effectiveness Research
Clinical Trial #: NCT02146274
Principal Investigator: Harish N. Shownkeen, MD
Contact: Komal Sharma, CRC, Komal.sharma@nm.org or Kathy Hansen, RN, CRC, Kathy.hansen@nm.org, 630.933.6107

Learn more at Clinicaltrials.gov2


Stroke

Study: MaRISS: Mild and Rapidly Improving Stroke Study
Clinical Trial #: NCT02072681
Principal Investigator: Harish N. Shownkeen, MD
Contact: Komal Sharma, CRC, Komal.sharma@nm.org or Kathy Hansen, RN, CRC, Kathy.hansen@nm.org, 630.933.6107

Learn more at Clinicaltrials.gov2


Ischemic Stroke

Study: Implant for Augmentation of Cerebral Blood Flow Trial, Effectiveness and Safety in a 24 Hour Window (ImpACT-24 B)
Details: A Multicenter, Randomized, Double Blind, Sham Control, Parallel Arm Trial to Assess Safety and Effectiveness of the Ischemic Stroke System ISS, as an Adjunct to Standard of Care in Subjects with Acute Ischemic Stroke
Clinical Trial #: NCT00826059
Principal Investigator: Harish N. Shownkeen, MD
Contact: Komal Sharma, CRC, Komal.sharma@nm.org or Kathy Hansen, RN, CRC, Kathy.hansen@nm.org, 630.933.6107

Learn more at Clinicaltrials.gov2


Stroke

Study: RESPECT ESUS: Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate (110 mg or 150 mg, oral b.i.d.) versus acetylsalicylic acid (100 mg oral q.d.) in patients with Embolic Stroke of Undetermined Source
Clinical Trial #: NCT02239120
Principal Investigator: Konstantin Dzamashvili, MD

Learn more at Clinicaltrials.gov2


Legal Information
1

In the spirit of keeping you well-informed, the physician(s) identified are neither agents nor employees of Northwestern Memorial HealthCare or any of its affiliate organizations. They have selected our facilities as places where they want to treat and care for their private patients.

2

By clicking on these websites, you are leaving the Northwestern Medicine website. These websites are independent resources. Northwestern Medicine does not operate or control the content of these websites. By visiting these websites, you agree to this third party’s terms of use for their website.